Placeholder

Letter from the Editor

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1767.

Product Description

They all may not be ready to go from the dish to the docks, but biotechnology companies are in a much better position to become integrated entities, maintaining more control over their innovative products and technologies.
According to Ernst & Young, there are more than 1,200 biotechnology companies in the U.S., of which 300 are publicly held. There have been 133 biotechnology drug products and vaccines approved by the FDA. Of the biotech medicines on the market, more than half were approved in the past five years. In 2001, the FDA approved 16 new biotechnology-based medicines and vaccines, as well as eight new indications for previously approved biotech products. There are more than 350 biotech drug products and vaccines currently in clinical trials targeting more than…

FEEDBACK